Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets

BACKGROUND. Molecular alterations of the PI3K and Ras pathways often occur in human cancer. In this trial, the pharmacokinetics, toxicity, and activity of two drugs inhibiting these pathways—everolimus and sorafenib—were investigated. METHODS. Thirteen patients with progressing solid tumors were tre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Toffalorio, Francesca, Spitaleri, Gianluca, Catania, Chiara, Dal Zotto, Laura, Noberasco, Cristina, Delmonte, Angelo, Santarpia, Mariacarmela, Vecchio, Fabio, Brunelli, Veronica, Rampinelli, Cristiano, Barberis, Massimo, Fumagalli, Caterina, Zucchetti, Massimo, Zangarini, Monique, Diena, Tullia, Danesi, Romano, de Braud, Filippo, De Pas, Tommaso
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2014
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983818/
https://ncbi.nlm.nih.gov/pubmed/24674875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0335
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars